PMID- 38008299
OWN - NLM
STAT- MEDLINE
DCOM- 20240505
LR  - 20240508
IS  - 1873-0183 (Electronic)
IS  - 1568-9972 (Linking)
VI  - 23
IP  - 3
DP  - 2024 Mar
TI  - New onset sarcoidosis following biologic treatment in patients with seronegative 
      inflammatory arthritis: A case series and systematic literature review.
PG  - 103481
LID - S1568-9972(23)00215-X [pii]
LID - 10.1016/j.autrev.2023.103481 [doi]
AB  - OBJECTIVE: To report cases of new onset sarcoidosis upon biologic (bDMARDs) 
      treatment administration in patients with seronegative inflammatory arthritis in 
      a real-life cohort, alongside a systematic literature review (SLR) on this topic. 
      METHODS: We performed a retrospective analysis on clinical records of patients 
      with seronegative arthritis followed up in a monocentric cohort who underwent 
      bDMARDs treatment due to the underlying rheumatic disease and described any newly 
      diagnosed sarcoidosis in this cohort. Only ascertained cases with available 
      radiological and/or histological documentation were considered. A SLR on 
      new-onset sarcoidosis in seronegative arthritis receiving bDMARDs was performed 
      across MEDLINE (through PubMed), Scopus and Ovid (Cochrane, Embase) electronic 
      databases using appropriate strings. RESULTS: In our cohort, 4 new-onset cases of 
      sarcoidosis were reported among patients with seronegative inflammatory arthritis 
      receiving biologics. Three out of 4 patients were receiving anti-tumor necrosis 
      factor alpha (TNFalpha) while 1 patient was on secukinumab (anti-IL17A) prior to 
      sarcoidosis onset. The SLR disclosed 46 new-onset sarcoidosis cases upon 
      biological treatment for seronegative arthritis, of whom 43 occurred during 
      treatment with anti-TNFalpha, while 3 during anti-IL-17A therapy. In our cohort as 
      well as in the majority of cases reported in the SLR, sarcoidosis presented with 
      lymph nodal and lung involvement and displayed a benign course with spontaneous 
      resolution in about 1 fourth of the cases. CONCLUSION: The use of biologics may 
      relate to the onset of sarcoidosis; hence, clinicians must remain aware of the 
      potential occurrence or reactivation of sarcoidosis when starting biologic 
      treatment in patients with inflammatory arthritis, performing adequate patient 
      assessment and surveillance. Since TNFalpha inhibitors may represent a therapeutic 
      option for sarcoidosis, further evaluation on larger cohorts is needed to 
      investigate any causal link with the development of sarcoidosis.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Donzella, Denise
AU  - Donzella D
AD  - Academic Rheumatology Centre, Dipartimento di Scienze Cliniche e Biologiche 
      Universita di Torino - AO Mauriziano di Torino, Turin, Italy.
FAU - Bellis, Elisa
AU  - Bellis E
AD  - Academic Rheumatology Centre, Dipartimento di Scienze Cliniche e Biologiche 
      Universita di Torino - AO Mauriziano di Torino, Turin, Italy.
FAU - Campisi, Paola
AU  - Campisi P
AD  - Pathology Unit, Mauriziano Hospital, Turin, Italy.
FAU - Crepaldi, Gloria
AU  - Crepaldi G
AD  - Academic Rheumatology Centre, Dipartimento di Scienze Cliniche e Biologiche 
      Universita di Torino - AO Mauriziano di Torino, Turin, Italy.
FAU - Data, Valeria
AU  - Data V
AD  - Academic Rheumatology Centre, Dipartimento di Scienze Cliniche e Biologiche 
      Universita di Torino - AO Mauriziano di Torino, Turin, Italy.
FAU - Dapavo, Paolo
AU  - Dapavo P
AD  - Section of Dermatology, Department of Medical Sciences, University of Turin, 
      Turin, Italy.
FAU - Lomater, Claudia
AU  - Lomater C
AD  - Academic Rheumatology Centre, Dipartimento di Scienze Cliniche e Biologiche 
      Universita di Torino - AO Mauriziano di Torino, Turin, Italy.
FAU - Marucco, Elena
AU  - Marucco E
AD  - Academic Rheumatology Centre, Dipartimento di Scienze Cliniche e Biologiche 
      Universita di Torino - AO Mauriziano di Torino, Turin, Italy.
FAU - Saracco, Marta
AU  - Saracco M
AD  - Academic Rheumatology Centre, Dipartimento di Scienze Cliniche e Biologiche 
      Universita di Torino - AO Mauriziano di Torino, Turin, Italy.
FAU - Gatto, Mariele
AU  - Gatto M
AD  - Academic Rheumatology Centre, Dipartimento di Scienze Cliniche e Biologiche 
      Universita di Torino - AO Mauriziano di Torino, Turin, Italy.
FAU - Iagnocco, Annamaria
AU  - Iagnocco A
AD  - Academic Rheumatology Centre, Dipartimento di Scienze Cliniche e Biologiche 
      Universita di Torino - AO Mauriziano di Torino, Turin, Italy. Electronic address: 
      annamaria.iagnocco@unito.it.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20231124
PL  - Netherlands
TA  - Autoimmun Rev
JT  - Autoimmunity reviews
JID - 101128967
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biological Products)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Antirheumatic Agents/therapeutic use/adverse effects
MH  - Arthritis/drug therapy/etiology
MH  - Biological Products/adverse effects/therapeutic use
MH  - Retrospective Studies
MH  - *Sarcoidosis/diagnosis
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
OTO - NOTNLM
OT  - Biologic treatment
OT  - Sarcoidosis
OT  - Seronegative inflammatory arthritis
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/11/27 00:43
MHDA- 2024/05/06 00:52
CRDT- 2023/11/26 19:27
PHST- 2023/11/06 00:00 [received]
PHST- 2023/11/21 00:00 [accepted]
PHST- 2024/05/06 00:52 [medline]
PHST- 2023/11/27 00:43 [pubmed]
PHST- 2023/11/26 19:27 [entrez]
AID - S1568-9972(23)00215-X [pii]
AID - 10.1016/j.autrev.2023.103481 [doi]
PST - ppublish
SO  - Autoimmun Rev. 2024 Mar;23(3):103481. doi: 10.1016/j.autrev.2023.103481. Epub 
      2023 Nov 24.